NYSE · Medical - Devices

Smith & Nephew SNATS, Inc. (SNN) Stock

$29.06 -0.10% NYSE: SNN Healthcare

Valuation

MetricValue
Price$29.06
Market Cap$12.16B
P/E Ratio17.48
P/B Ratio2.17
P/S Ratio1.75
EPS (TTM)$1.44
52-Week High$37.51
52-Week Low$26.12
Dividend Yield2.30%

Financials & Margins

MetricValue
ROE12.25%
ROA5.81%
ROCE11.81%
Gross Margin68.01%
Operating Margin16.27%
Net Margin10.08%
Debt/Equity0.73
Current Ratio2.57

Annual Financials (USD)

Metric20212022202320242025
Revenue$5.2B$5.2B$5.5B$5.8B$6.2B
Operating Profit$593.0M$450.0M$425.0M$657.0M$794.0M
Net Profit$524.0M$223.0M$263.0M$412.0M$625.0M
EPS$1.20$0.50$1.20$0.94$1.44
Op Margin11.4%8.6%7.7%11.3%12.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$10.9B$10.0B$10.0B$10.4B$10.5B
Total Liabilities$5.4B$4.7B$4.8B$5.1B$5.2B
Cash$1.3B$350.0M$302.0M$619.0M$557.0M
Borrowings$3.3B$2.9B$3.1B$3.3B$3.3B

Latest News

Smith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons GlobeNewswire · Jul 15, 2026 New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications GlobeNewswire · Jul 9, 2026 New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions GlobeNewswire · Jul 9, 2026 Alkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors. Barrons.com · Jul 3, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading MT Newswires · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$877.0M$468.0M$608.0M$987.0M$1.3B
Investing Cash Flow$-1.1B$-830.0M$-875.0M$-950.0M$-839.0M
Financing Cash Flow$-257.0M$-556.0M$179.0M$-704.0M$-485.0M
Net Cash Flow$-466.0M$-941.0M$-44.0M$317.0M$-62.0M
Free Cash Flow$469.0M$110.0M$181.0M$606.0M$852.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.52
EV / EBITDA8.56
FCF Yield7.60%
Quick Ratio1.11
Interest Coverage6.66
Return 1Y-21.66%
Return 3Y23.10%
Return 5Y-10.13%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATECAlphatec Holdings, Inc. $10.46 -4.30% -15.18 $1.62B 0.00%
CNMDCONMED Corporation $46.72 -0.89% 25.41 $1.40B 1.73%
ENOVEnovis Corporation $19.59 +1.24% -0.96 $1.13B 0.00%
GMEDGlobus Medical, Inc. $76.71 -2.70% 19.04 $10.30B 0.00%
IARTIntegra LifeSciences Holdings Corporation $13.21 -2.37% -176.57 $1.03B 0.00%

About Smith & Nephew SNATS, Inc.

Smith & Nephew SNATS, Inc. is led by CEO Deepak S Nath, employs 17,818 people, headquartered in Watford, GB, publicly traded since 1999.

Smith & Nephew SNATS, Inc. (SNN) stock trades at $29.06 with a market capitalization of $12.16B. The stock is valued at a price-to-earnings (P/E) ratio of 17.48, price-to-book of 2.17, price-to-sales of 1.75. Over the past 52 weeks the stock has ranged between $26.12 and $37.51, and currently trades 22.5% below its 52-week high. It pays a dividend yielding 2.30%.

On profitability, Smith & Nephew SNATS, Inc. generates a return on equity (ROE) of 12.25%, return on capital employed of 11.81%, an operating margin of 16.27%, a net profit margin of 10.08%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.